Relmada Hopes Open-Label Efficacy, Safety Bolster Profile Of Depression Candidate

With a pair of Phase III setbacks due to high placebo response, Relmada reports positive efficacy and safety data from an open-label trial while awaiting data from two ongoing pivotal studies for REL-1017, an NMDA antagonist.